
Novartis Gets Phase 3-Ready Rare Kidney Disease Drug via $800M Regulus Acquisition
Novartis has made kidney disorders an area of focus, and it’s now adding a new drug prospect through a deal to acquire Regulus Therapeutics, a biotech with a drug ready for pivotal testing in a rare renal disease that has limited treatment options. The …